Ardhendu Kumar Mandal, Ph.D.

Principal Technical Officer, Central Instrumentation Facility

Research Focus

Nanoparticles mediated delivery: • To optimize different cargos in nanoparticle formulation • To characterize the nanoparticulated moieties • To study the metabolic stability, the cellular uptake and the cytotoxicity efficiencies in vitro • To study the biodistribution and the pharmacokinetics profiles in vivo • To investigate the mechanisms of disease development and their inhibitions by potent cargos in vitro and in vivo • To evaluate the therapeutic efficacies of nanoparticulated bioactive cargos against diseases.

Research Interest

To study the molecular mechanisms of toxicants / parasites -induced carcinogenesis in initiation, promotion, progression and metastasis stages as well as in cell cycle phases on the generation of ROS, oxidative stress, activations of transcription factors, receptors, gene expression, cell migration and invasion, actin filament reorganization, transformation, tumor suppressor genes and oncogenes, DNA damage and repair, cell cycle regulation, apoptosis utilizing signal transduction pathways such as PI-3K/Akt/JNKs/ERKs/MAPK/calcium signaling, Wnt/β-catenin, STATs, MMPs, immunological alterations, metabolic disorders including microarray analysis, real time RT-PCR, protein and gene sequencing, protein X-ray crystallography, liquid chromatography, mass spectrometry, SEM, TEM, AFM, FT-IR, SPR, etc. for characterizations and to standardize the above mentioned mechanism-based prevention and control of cancer and other diseases including molecular epigenetics and stem cells biology using different drug compounds (herbal and synthetic) and other components such as proteins, peptides, antibodies and genes encapsulated in nanoparticulated delivery systems e.g. liposomes, nanoparticles (nanocapsules, metals, non-metals, DNA tetrahedron) and exosomes to combat also drug resistance by passive and active (ligand-receptor, antigen-antibody and aptamer mediated) targeting as chemopreventive agents against key marker molecule/s in vitro and in vivo.


  • 2016-Present: Principal Technical Officer, CSIR-IICB, Kolkata
  • 2014-2015: Postdoctoral Research Associate: Arizona State University, Tempe, AZ, USA with Prof. Sidney Hecht
  • 2009-2010: Postdoctoral Research Scholar: University of Kentucky, Lexington, KY, USA, with Prof. Xianglin Shi
  • 2006: Ph.D. Jadavpur University (IICB), India with Dr. Nirmalendu Das (Scientist, IICB) on “Drug Targeting in Hepatocellular Disorders in Animal Model.”
  • 1994: M.S. in Life Sciences (Biochem, Org Chem, Cell Biol, Math & Stat, Inst, Syn Org Chem, Comput,   Genetics, Biophys, Microbiol, Rec DNA Tech, Syst, Pharmacol, Ecol, Dev Biol, Physiol, Biostat & Decis Analy, Enzymol, Bacteriol, Immunol, Dissert, Prof Prac, Adv Immunol, Adv Cell & Mol Biol) from Birla Institute of Technology and Science, Pilani.
  • 1985: B.Sc. in Physiology (Hons.) with Zoology (P), Botany (P) & English (L), from Surendranath College, Calcutta University.

Honours & Awards

  1. Awarded joining certificate as an Academic Editor of Asian Journal of Biochemistry, Genetics and Molecular Biology, SCIENCEDOMAIN International (06/06/2022 - 05/06/2026).
  2. Acknowledged as Reviewer on the paper entitled “Elevated serum uric acid is associated with poor survival in advanced HCC patients and febuxostat improves prognosis in HCC rats”. Front Pharmacol Nov 2021; 12:778890. I.F. 5.810.
  3. Awarded Reviewer Certificate (No.SDI/HQ/PR/Cert/63902/ARD) from Asian Journal of Research in Medical and Pharmaceutical Sciences, SCIENCEDOMAIN International dated on December 16, 2020.
  4. Awarded Reviewer Certificate (No.SDI/HQ/PR/Cert/39890/Ard) from Journal of Pharmaceutical Research International, SCIENCEDOMAIN International dated on February 20, 2018.
  5. Awarded Reviewer Certificate from British Journal of Pharmacology dated on 24 February 2017.
  6. Awarded Leading Scientists of the World – 2015 in scientific research by International Biographical Centre at Cambridge, England.
  7. Post Doctoral Research Associateship (2014-15), Arizona State University, Tempe, Arizona, USA.
  8. Post Doctoral Research Scholarship (2009-10), University of Kentucky, (NIH Project, Bethesda, MD), USA.
  9. Ardhendu Kumar Mandal1, Rantu Paul2, Parthasarathi Bhattacharya2, Sibani Sarkar1, Nilanjan Ganguly1 and Snehasikta Swarnakar1 . “Matrix metalloproteinases mediated angiogenesis via P38 kinases signaling in idiopathic pulmonary fibrosis”. Awarded 1st Prize dated on 29-30 September 2012 presented (poster) in 10th All India Update in Pulmonary Medicine (PULMOCON-12) at CII-Suresh Neotia Centre, City Centre, Saltlake, Kolkata-64, India.
  10. Aparajita Ghosh, Ardhendu K. Mandal, Subhankar Das & Nirmalendu Das. “Galactosylated Liposomal Quercetin Targeting to Liver In Combating Arsenite Induced Hepatic Damage In Rat Model.” Awarded 2nd Prize dated on 12-13 Dec 2006 presented (poster) in workshop on Biomaterials and Biomedical devices at CG&CRI, Kolkata, India.

Patents & Publications


  1. Mandal AK*. Exosomes as endogenous nanovesicular delivery system in combating various diseases. Glob J Pharmaceu Sci 2023; 10(5):555796. DOI:10.19080/GJPPS.2023.10.555796. IF: 0.997.
  2. Mandal AK*. Gold nanoparticles as theranostic delivery system in combating various diseases. In Book: Tsygankova Victoria Anatolyivna, Editor. “Research Advances in Microbiology and Biotechnology Vol. 6”. India-United Kingdom: Book Publisher International, 2023; cp 8, pp 100-128. DOI: 10.9734/bpi/ramb/v6/5933B.      
  3. Mandal AK*. Selenium nanoparticles as delivery system against various diseases. Glob J Pharmaceu Sci 2023; 10(4):555794. DOI: 10.19080/GJPPS.2023.10.555794. IF: 0.997.
  4. Mandal AK*, Sarkar S. Aluminium nanomaterials as delivery system in combating diseases. Int J Curr Res 2023; 15(01):23431-23434. DOI: IF: 1.532. 
  5. Mandal AK*. Chromium induced developments of diseases and their inhibitions by cargos. Asian J Biochem Genet Mol Biol 2022; 12(4):108-119. DOI: 10.9734/AJBGMB/2022v12i4274.
  6. Mandal AK*. Mitochondrial targeting of potent nanoparticulated drugs in combating diseases. J Biomater Appl 2022; 37(4):614-633. DOI:10.1177/08853282221111656. IF: 2.712; 5 Yr. IF: 3.070.
  7. Mandal AK*. Silver nanoparticles as drug delivery system in combating infections and cancer. In Book: Farzaneh Mohamadpour, Editor. “Challenges and Advances in Pharmaceutical Research Vol. 4”. India-United Kingdom: Book Publisher International, 2022; cp 14, pp 165-179. DOI: 10.9734/bpi/capr/v4/16408D.
  8. Mandal AK*. Polycaprolactone nanoparticles as delivery vehicle in combating diseases. Ind J Appl Res 2022; 12(04): DOI:10.36106/ijar.
  9. Mandal AK*, Joardar A. Manganese nanomaterials as delivery system in combating diseases. Int J Curr Res 2021; 13(10):19306-19315. IF: 1.532.
  10. Mandal AK*. Melatonin as potent therapeutic drug in vesicular delivery application in combating diseases. Glob J Nanomed 2021; 5(4):555669. DOI:10.19080/GJN.2021.05.555669. IF:  0.949.
  11. Mandal AK*. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int J Polym Mater Polym Biomater 2021; 70(4):287-297. IF: 2.263.
  12. Mandal AK*. Poly alkyl cyanoacrylate nanoparticles as delivery vehicle in combating diseases. Int J Scient Res 2020; 9(11):10.36106/ijsr. 
  13. Mandal AK*. Gallium nanoparticles as delivery system against infectious diseases and cancer. Ind J Appl Res 2020; 10(10): DOI:10.36106/ijar.
  14. Mandal AK*. Copper nanomaterials as delivery system in combating infective agents and cancer. In Book: Lanzhuang Chen, Editor. “Recent Advances in Biological Research Vol. 2”. India-United Kingdom: Book Publisher International, 2019; cp 10, pp 100-111. 
  15. Mandal AK*. Titanium dioxide nanoparticles as delivery system against infections and cancer. Int J Curr Res 2019; 11(1):68-72.
  16. Mandal AK*. Hydroxyapatite nanoparticles as delivery system in combating various diseases. Int J Curr Adv Res 2018; 7(10C):15869-15877.
  17. Mandal AK*. Mesoporous silica nanoparticles as delivery system against diseases.  Int J Recent Sci Res 2018; 9(9C):28817-28825.
  18. Mandal AK*. Carbon nanotubes as delivery system in combating diseases. Int J Sci Res 2018; 7(8):1244-1250.
  19. Mandal AK*. Iron oxide nanoparticles as delivery system against diseases. Int J Curr Res 2018; 10(6):69957-69965. 
  20. Wang Y, Mandal AK, Son YO, Pratheeshkumar P, Wise JTF, Wang L, Zhang Z, Shi X, Chen Z. Roles of ROS, Nrf2, and autophagy in cadmium-carcinogenesis and its prevention by sulforaphane. Toxicol Appl Pharmacol 2018; 353:23-30. IF: 3.791.
  21. Mandal AK*. Zinc oxide nanoparticles as delivery system to combat diseases. Int J Curr Adv Res 2018; 7(5D):12469-12478.
  22. Mandal AK*. Gold nanoparticles as delivery system against diseases. Latvia, European Union: LAP LAMBERT Academic Publishing (SIA OmniScriptum Publishing) 2018; p. 1-45. 
  23. Mandal AK*. Vesicular drug delivery against leishmaniasis in animals:   A critical evaluation. Int J Curr Res 2018; 10(1):64103-64113.
  24. Mandal AK*, Ghosh A, Das N. Vesicular drug targeting in combating cerebral oxidative injury. Ind J Appl Res 2018; 8(1):287-292.
  25. Mandal AK*. Copper nanomaterials as drug delivery system against infectious agents and cancerous cells. J Appl Life Sci Int 2017; 15(4):38444.
  26. Mandal AK*. Gold nanomaterials as drug delivery system against diseases. Ann Res Rev Biol 2017; 19(6):37866.
  27. Mandal AK*. Silver nanoparticles as drug delivery vehicle against infections. Glob J Nanomed 2017; 3(2):555607.
  28. Sarkar S, Mandal A. Neurophysiological changes in oxidative injury: Involvement of calcium homeostasis and ER stress. JSM Alzheimer’s Dis Related Dementia 2017; 4(1):1033.
  29. Sana S, Ghosh S, Das N, Sarkar S and Mandal AK*. Vesicular melatonin efficaciently downregulates sodium fluoride-induced rat hepato and broncho TNF-α, TGF-β expressions and associated oxidative injury: A comparative study of liposomal and nanocapsulated forms. Int J Nanomed 2017; 12: 4059-4071. IF: 4.320. 
  30. Mandal AK*, Ghosh D, Sarkar S, Ghosh A, Swarnakar S and Das N. Nanocapsulated quercetin downregulates rat hepatic MMP-13 and controls diethylnitrosamine induced carcinoma. Nanomedicine (Lond) 2014; 9(15):2323-37. IF: 5.26. 
  31. Sarkar S, Mandal AK and Das N. Vesicular Antioxidants: Role in age-related cerebral oxidative injury. In Book: Armstrong D, Bharali DJ (Eds.). “Oxidative stress and Nanotechnology” Sr. Methods in Molecular Biology. New York, USA: Springer Science, A product of Humana Press, 2013; Vol.1028:221-30. IF: 1.29.
  32. Ghosh A, Sarkar S, Mandal AK and Das N (2013). Neuroprotective role of nanoencapsulated quercetin in combating ischemia-reperfusion induced neuronal damage in young and aged rats. PLoS One 2013; 8(4):e57735. IF: 4.092.  
  33. Wang X, Mandal AK, Saito H, Pullian JF, Lee EY, Ke ZJ, Lu J, Ding SZ, Li L, Shelton BJ, Tucker T, Evers BM, Zhang Z, Shi X. Arsenic and chromium in drinking water promote tumorigenesis in a mouse colitis-associated colorectal cancer model and the potential mechanism is ROS-mediated Wnt/β-catenin signaling pathway. Toxicol Appl Pharmacol 2012; 262(1):11-21. IF: 4.45.
  34. Ghosh D, Thakur Choudhury S, Ghosh S, Mandal AK, Sarkar S, Ghosh A, Das Saha K, Das N. Nanocapsulated Curcumin: Oral chemopreventive formulation against Diethylnitrosamine induced Hepatocellular Carcinoma in rat‏. Chem Biol Interact 2012; 195(3):206-214. IF: 2.832.
  35. Ghosh A, Ghosh D, Sarkar S, Mandal AK, Thakurchoudhury S and Das N. Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine induced hepatocarcinoma in rats. Eur J Cancer prevent 2012; 21(1), 32-41. IF: 2.536.
  36. Ghosh S, Dungdung SR, Thakur Choudhury S, Mandal AK, Sarkar S, Ghosh D and Das N. Encapsulation of the flavanoid Quercetin with an arsenic chelator into nanocapsules enables the simultaneous delivery of hydrophobic and hydrophilic drugs with a synergistic effect against chronic arsenic accumulation and oxidative stress. Free Radic Biol Med 2011; 51(10), 1893-902. IF: 6.081.
  37. Ghosh A, Mandal AK, Sarkar S and Das N. Hepatoprotective and neuroprotective activity of liposomal quercetin in combating chronic arsenic induced oxidative damage in liver and brain of rats. Drug Deliv 2011; 18(6), 451-9. IF: 1.246. 
  38. Ghosh S, Das N, Mandal AK, Dungdung SR and Sarkar S. Mannosylated Liposomal CDP-Choline prevent age related global moderate Cerebral Ischemia Reperfusion induced mitochondrial Cytochrome C release in rat brain. Neurosci 2010; 171(4), 1287-1299. IF: 3.215. 
  39. Ghosh D, Ghosh S, Sarkar S, Ghosh A, Das N, Saha KD, Mandal AK*. Quercetin in vesicular delivery systems: Evaluation in combating arsenic-induced acute liver toxicity associated gene expression in rat model. Chem Biol Interact 2010; 186, 61-71. IF: 2.832.
  40. Dey H, Das N, Mandal AK. Liposomal quercetin in combating CCl4 induced oxidative liver damage. In Book: Sayyed RZ, Patil AS, editors. “Biotechnology: Emerging Trends”. Jodhpur, India: Scientific Publishers 2009; cp B4, pp 211-216.
  41. Das N, Mandal AK, Sarkar S, Ghosh A. Liposomal flavonoid in combating age related cerebral oxidative damage. In Book: Mishra CSK, Champagne P, editors. “Biotechnol Appl” New Delhi: IK Int Publ Ho Pvt Ltd. 2009; pp 138-152.   
  42. Ghosh A, Mandal AK, Sarkar S, Panda S, Das N. Nanoencapsulation of quercetin enhances its dietary efficacy in combating arsenic-induced oxidative damage in liver and brain of rats. Life Sci 2009;  84(3-4), 75-80. IF: 2.451. 
  43. Das S, Mandal AK, Ghosh A, Panda S, Das N, Sarkar S. Nanoparticulated Quercetin in combating age related cerebral oxidative injury. Curr Aging Sci 2008; 1(3), 169-174.
  44. Das N, Sarkar S, Mandal AK. Flavonoidal nanoparticle in combating age related cerebral oxidative injury. In Book: Prof. (Dr.) Samar Banerjee, West Bengal, India, editor. Proceedings of XVth Annual Conference of API, WB Branch, 2008; 124-130.
  45. Mandal AK, Das S, Mitra M, Chakrabarti RN, Chatterjee M, Das N. Vesicular flavonoid in combating diethylnitrosamine induced hepatocarcinoma in rat model.  J Experiment Therapeut Oncol 2008; 7(2), 123-133.
  46. Mandal AK, Das S, Basu MK, Chakrabarti RN, Das N. Hepatoprotective activity of liposomal flavonoid against arsenite induced liver fibrosis.  J Pharmacol Experiment Therapeut 2007; 320(3), 994-1001. IF: 4.017. 
  47. Mandal AK, Das N. Sugar coated liposomal flavonoid: A unique formulation in combating carbontetrachloride induced hepatic oxidative damage. J Drug Target 2005; 13(5), 305-315. IF: 2.491.
  48. Mitra M, Mandal AK, Chatterjee TK, Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT 81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 2005; 13(5), 285-293. IF: 2.491.
  49. Bhattacharyya A, Mukherjee M, Mandal A, Duttagupta S. Analysis of isoenzyme patterns of single cell clones of Leishmania of Indian origin. Sci Culture 2005; 71(5/6):201.
  50. Mandal AK, Sinha J, Mandal S, Mukhopadhyay S, Das N. Targeting of Liposomal flavonoid to liver in combating hepatocellular oxidative damage. Drug Deliv 2002; 9, 181-185. IF: 1.246.
  51. Bhattacharyya A, Roy M, Mandal A, Duttagupta S. Effects of metal ions and other anti-leishmanial drugs on stibanate resistant Leishmania donovani promastigotes of Indian origin. Curr Sci 2001; 81 (11), 1470-1473. IF: 0.782.
  52. Pal S, Mandal A, Duttagupta S. Studies on stibanate resistant Leishmania donovani isolates of Indian origin. Ind J Experiment Biol 2001; 39, 249-254. IF: 0.55.  
  53. Roy C, Mandal A, Duttagupta S. Serodiagnosis of Indian kala-azar by elisa using purified Leishmania specific antigens. Ind J Clinic Biochem 1997; 12 (suppl 1), 62. 

*Corresponding author

Administrative Responsibilities:

  • Acting as Test Facility Manager (TFM) in analytiCSIR web portal since 08/04/2019.